Navigation Links
Clot-busting drug helps revive cardiac arrest patients

Using a "clot buster" drug normally reserved for treating patients during a heart attack, emergency room doctors were able to double the number of patients who could be revived from cardiac arrest. This sudden loss of heart function occurs in more than 260,000 people a year nationwide ?and at least 93 percent of them die.

"Clot-busting agents show promise as a new therapy for this abrupt and catastrophic loss of heart function," said William P. Bozeman, M.D., an emergency medicine specialist at Wake Forest University Baptist Medical Center and lead author on the study, reported in the June issue of the journal Resuscitation and available now on-line.

The pilot study involved patients with cardiac arrest who didn't respond to standard therapy. Of 50 patients who received clot-busting therapy, 26 percent were revived, compared to 12 percent of patients who got standard therapy alone. However, not all patients who were revived lived long enough to be discharged from the hospital.

The study was conducted while Bozeman was at the University of Florida's Shands Medical Center and included three affiliated hospitals. It involved patients with cardiac arrest, which often occurs when the electrical signals that regulate the heart become erratic or irregular because of a heart attack, coronary heart disease, a blood clot in the lungs, or other causes. The heart stops beating and the brain starts to suffer permanent damage within four to six minutes. Death quickly follows.

The standard treatment for cardiac arrest is Advanced Cardiac Life Support (ACLS) measures, which include cardiopulmonary resuscitation (CPR), drugs such as adrenaline, and defibrillation, an electric shock to the heart.

"We are in dire need of additional treatment options for sudden cardiac arrest because there is only a 5 percent to 7 percent survival rate using interventions we now have," said Bozeman, associate professor of emergency medicine. "We hope this small study will lead the way for additional research on this promising new approach."

Fifty patients who did not respond to treatment with ACLS interventions were given the clot-buster tenecteplase, known medically as a fibrinolytic agent. Spontaneous circulation returned in 26 percent of these patients. Four percent survived and were discharged from the hospital and had normal brain function. In the group of 113 patients who received ACLS alone, 12 percent were revived, but none lived long enough to leave the hospital.

The patients who were treated with tenecteplase had been receiving ACLS measures for a mean of 30 minutes and received a mean of eight doses of standard medications.

"The study supports the use of fibrinolytic drugs in select cases of cardiac arrest where patients don't respond to standard therapy, and it reinforces the need for additional studies of this therapy," said Bozeman.

Tenecteplase is approved by the Food and Drug Administration for treating patients suffering from acute heart attacks or pulmonary embolism (blockage of an artery in the lungs that can cause heart rhythm problems). Clot-busting drugs aren't typically used in patients with cardiac arrest because of concerns that the chest compressions used during CPR could cause bleeding complications.

Several small studies, however, have suggested that clot-busting medications, in combination with CPR, may improve overall survival. Bozeman's study is the first in the United States to observe the effects of treatment with tenecteplase and with standard therapy.

Tenecteplase was developed and is marketed by Genentech Inc. of South San Francisco as TNKaseTM. Genentech also provided support for the study.


'"/>

Source:Wake Forest University Baptist Medical Center


Related biology news :

1. Jumping gene helps explain immune systems abilities
2. Protein helps regulate the genes of embryonic stem cells
3. Scientists reveal the shape of a protein that helps retroviruses break into cells
4. Thai spice helps cut blood sugar swings
5. Chemists synthesize molecule that helps body battle cancers, malaria
6. Ancient DNA helps clarify the origins of two extinct New World horse species
7. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
8. Study: Well-known protein helps stem cells become secretory cells
9. Beyond genes: Lipid helps cell wall protein fold into proper shape
10. Simple sea sponge helps scientists understand tissue rejection
11. New technique helps identify multiple DNA regulatory sites
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... ... April 25, 2017 , ... L3 ... to announce the company is now a certified iMedNet eClinical and Electronic Data ... enables the company’s clinical research team to build, customize and manage clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... Covalent Metrology ... Analytical Services unit provides high-quality data to clients, both faster and ... of receipt. There are no price premiums, and customers are welcome to participate ...
(Date:4/24/2017)... April 24, 2017  Dante Labs announced today the offer ... 850 (ca. $900). While American individuals have been able to ... Europeans can access WGS below EUR 1,000. The ... leveraging genetic information to make informed decisions about disease monitoring, ... ...
(Date:4/21/2017)... Conn. (PRWEB) , ... April 21, 2017 , ... ... (CI) and Webster Bank, today announced first round funding to three startups through ... provide early-stage financial support to new business startups affiliated with UConn. , The ...
Breaking Biology Technology: